Relay Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Relay Therapeutics Inc RLAY.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -67 cents. The mean expectation of twelve analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -71 cents to -39 cents per share.

• Reported revenue was zero​; analysts expected $6.08 million.

• Relay Therapeutics Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $76 million.

• Relay Therapeutics Inc shares had fallen by 9.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Relay Therapeutics Inc is $19.00

This summary was machine generated from LSEG data February 27 at 09:14 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)